Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 5
Submit an article Journal homepage
1,899
Views
38
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial

Tadeusz RobakDepartment of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland; Correspondence[email protected]
,
Krzysztof WarzochaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
,
K. Govind BabuKidwai Memorial Institute of Oncology, Bangalore, India; ;HCG Curie Centre of Oncology, Bangalore, India;
,
Yaroslav KulyabaMakiivka City Hospital #2 of Donetsk Region, Makiivka, Ukraine;
,
Kazimierz KuliczkowskiDepartment of Medical Oncology, Wrocław Medical University, Wrocław, Poland;
,
Kudrat AbdulkadyrovRussian Research Institute of Hematology and Transfusiology, St. Petersburg, Russia;
,
Javier LoscertalesHospital Universitario de La Princesa, IIS-IP, Madrid, Spain;
,
Iryna KryachokOncohematology Department, National Cancer Institute, Kiev, Ukraine;
,
Janusz KłoczkoMedical University of Bialystok, Bialystok, Poland;
,
Grygoriy RekhtmanKhmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine;
,
Wojciech HomendaDepartment of Hematology, Janusz Korczak Hospital, Słupsk, Poland;
,
Jerzy Z. BłońskiDepartment of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland;
,
Astrid McKeownNovartis, Uxbridge, UK;
,
Michele M. GorczycaGlaxoSmithKline, Collegeville, PA, USA;
,
Jodi L. CareyGlaxoSmithKline, Collegeville, PA, USA;
,
Chai-Ni ChangNovartis, Research Triangle Park, Durham, NC, USA;
,
Steen LisbyGenmab, Copenhagen, Denmark;
,
Ira V. GuptaNovartis, King of Prussia, PA, USA;
&
Sebastian GrosickiDepartment of Cancer Prevention, Faculty of Public Heath, Medical University of Silesia, Katowice, Poland
 show all
Pages 1084-1093 | Received 09 Jun 2016, Accepted 01 Sep 2016, Published online: 12 Oct 2016

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (9)

Pawel Robak & Tadeusz Robak. (2023) Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. Expert Opinion on Biological Therapy 23:1, pages 21-35.
Read now
Jennifer L. Crombie & Jennifer R. Brown. (2021) The future of antibody therapy in chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 26:3, pages 323-336.
Read now
Iwona Hus, Aleksander Salomon-Perzyński & Tadeusz Robak. (2020) The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 20:7, pages 799-812.
Read now
Sebastian Grosicki, Ewa Lech-Maranda, Kanakasetty Govind Babu, Justyna Rybka, Elena Litvinskaya, Javier Loscertales, Iryna Kriachok, Janusz Kłoczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Tommaso Stefanelli, Ghislaine Vincent, Hiya Banerjee & Tadeusz Robak. (2020) A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial. Leukemia & Lymphoma 61:7, pages 1748-1751.
Read now
Driss Chaoui, Maya Hacini, Olivier Fitoussi, Lionel Karlin, Yazid Arkam, Eric Jourdan, Hubert Orfeuvre, Laurent Voillat, Laurence Sanhes, Stéphane Leprêtre, Kun Lun Liu, Marly Barry, Adrian Tempescul, Marie-Sarah Dilhuydy, Abdelaziz Chaib, Borhane Slama, Jean Luc Labourey, Omar Benbrahim, Brigitte Dreyfus, Béatrice Mahé, Marc Maynadié, Alain Delmer, Chahinez Benkanoun, Frédéric Boissard, Sophie Gandon, Kalaivani Veerabudun & Sylvain Choquet. (2019) Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study. Leukemia & Lymphoma 60:6, pages 1563-1567.
Read now
J. M. L. Casan, J. Wong, M. J. Northcott & S. Opat. (2018) Anti-CD20 monoclonal antibodies: reviewing a revolution. Human Vaccines & Immunotherapeutics 14:12, pages 2820-2841.
Read now
Anna Puła, Konrad Stawiski, Marcin Braun, Elżbieta Iskierka-Jażdżewska & Tadeusz Robak. (2018) Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. Leukemia & Lymphoma 59:5, pages 1084-1094.
Read now
Tadeusz Robak, Krzysztof Warzocha, K. Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, Javier Loscertales, Iryna Kryachok, Janusz Kłoczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Z. Błoński, Astrid McKeown, Chai-Ni Chang, Vasudha Bal, Steen Lisby, Ira V. Gupta & Sebastian Grosicki. (2017) Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Leukemia & Lymphoma 58:7, pages 1598-1606.
Read now
Abdallah Abou Zahr, Prithviraj Bose & Michael J. Keating. (2017) Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 18:9, pages 857-873.
Read now

Articles from other publishers (29)

Muhammad Hossein Ashoub, Amirreza Naseri, Parisa Mohammadi & Masoud Mohammadi. (2023) Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis. Annals of Hematology 102:6, pages 1301-1306.
Crossref
Zekhethelo A. Mkhwanazi, Tawanda M. Nyambuya, Snenhlanhla A. Mfusi & Bongani B. Nkambule. (2022) Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors. BMC Cancer 22:1.
Crossref
Stephanos Vassilopoulos, Fadi Shehadeh, Markos Kalligeros, Quynh-Lam Tran, Fred Schiffman & Eleftherios Mylonakis. (2022) Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. Frontiers in Pharmacology 13.
Crossref
Andres Forero‐Torres, Jason Claud Chandler, Swaminathan P. Iyer, Abraham S. Kanate, Michelle Quinlan, Petra Hoever, Miguel Izquierdo, Jaclyn Davis & Sumit Madan. (2022) Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma. Clinical Pharmacology in Drug Development 11:9, pages 1099-1109.
Crossref
Biswanath Basu, Andrea Angeletti, Bilkish Islam & Gian Marco Ghiggeri. (2022) New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?. Frontiers in Immunology 13.
Crossref
Smita Kumari, Dia Advani, Sudhanshu Sharma, Rashmi K. Ambasta & Pravir Kumar. (2021) Combinatorial therapy in tumor microenvironment: Where do we stand?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:2, pages 188585.
Crossref
Nil Albiol, Miguel Arguello-Tomas & Carol Moreno. (2021) The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. Current Opinion in Oncology 33:6, pages 670-680.
Crossref
David Allsup, Dena Howard, Jake Emmerson, Anna Hockaday, Andy Rawstron, Jamie B. Oughton, Adrian Bloor, David Phillips, Amit Nathwani, Shankara Paneesha, Deborah Turner, Talha Munir & Peter Hillmen. (2021) COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology 194:3, pages 646-650.
Crossref
Mathias J. Rummel, Ann Janssens, David MacDonald, Mary‐Margaret Keating, Jan M. Zaucha, Jaclyn Davis, Janet Lasher, Chaitali Babanrao Pisal, Miguel Izquierdo & Jonathan W. Friedberg. (2021) A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study). British Journal of Haematology 193:6, pages 1123-1133.
Crossref
Clifford M. Csizmar & Stephen M. Ansell. (2021) Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. International Journal of Molecular Sciences 22:7, pages 3302.
Crossref
Barbara Vannata, Anna Vanazzi, Mara Negri, Sarah Jayne Liptrott, Anna Amalia Bartosek, Monica Miani, Alessandro Di Sanzo, Franco Cavalli, Emanuele Zucca & Anastasios Stathis. (2020) A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas. Hematological Oncology 39:1, pages 60-65.
Crossref
Piotr Smolewski & Tadeusz Robak. (2021) Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. Kompass Onkologie 8:2, pages 59-69.
Crossref
Piotr Smolewski & Tadeusz Robak. (2021) Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. Acta Haematologica 144:4, pages 365-379.
Crossref
Sattva S Neelapu, Sherry Adkins, Stephen M Ansell, Joshua Brody, Mitchell S Cairo, Jonathan W Friedberg, Justin P Kline, Ronald Levy, David L Porter, Koen van Besien, Michael Werner & Michael R Bishop. (2020) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. Journal for ImmunoTherapy of Cancer 8:2, pages e001235.
Crossref
Vishwanath Sathyanarayanan, Christopher R. Flowers & Swaminathan P. Iyer. (2020) Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. JCO Global Oncology:6, pages 1124-1133.
Crossref
Annika Scheffold & Stephan Stilgenbauer. (2020) Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm. Current Oncology Reports 22:2.
Crossref
Francesca R Mauro, Stefano Molica, Stefano Soddu, Fiorella Ilariucci, Marta Coscia, Francesco Zaja, Emanuele Angelucci, Francesca Re, Anna Marina Liberati, Alessandra Tedeschi, Gianluigi Reda, Daniela Pietrasanta, Alessandro Gozzetti, Roberta Battistini, Giovanni Del Poeta, Caterina Musolino, Mauro Nanni, Alfonso Piciocchi, Marco Vignetti, Antonino Neri, Francesco Albano, Antonio Cuneo, Ilaria Del Giudice, Irene Della Starza, Maria Stefania De Propris, Sara Raponi, Anna R Guarini & Robin Foà. (2020) High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica.
Crossref
Yoshikane Kikushige. (2020) Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. Journal of Clinical and Experimental Hematopathology 60:4, pages 146-158.
Crossref
Sagun Parakh, Dylan King, Hui K. Gan & Andrew M. Scott. 2020. Current Immunotherapeutic Strategies in Cancer. Current Immunotherapeutic Strategies in Cancer 1 70 .
Jeff P. Sharman. (2019) Targeting CD20: teaching an old dog new tricks. Hematology 2019:1, pages 273-278.
Crossref
John C. ByrdPeter Hillmen, Susan O’BrienJacqueline C. BarrientosNishitha M. ReddySteven CoutreConstantine S. TamStephen P. MulliganUlrich JaegerPaul M. BarrRichard R. FurmanThomas J. KippsPatrick ThorntonCarol MorenoMarco MontilloJohn M. PagelJan A. BurgerJennifer A. WoyachSandra Dai, Remus Vezan, Danelle F. James & Jennifer R. Brown. (2019) Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 133:19, pages 2031-2042.
Crossref
Deyan Y. Yosifov, Christine Wolf, Stephan Stilgenbauer & Daniel Mertens. (2019) From Biology to Therapy: The CLL Success Story. HemaSphere 3:2, pages e175.
Crossref
Matthew J. Barth & Stanton C. Goldman. 2019. Resistance to Targeted Therapies in Lymphomas. Resistance to Targeted Therapies in Lymphomas 27 55 .
Tadeusz Robak. 2019. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 107 119 .
Lorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs & Pilar Nava-Parada. (2018) An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:8, pages 508-518.e14.
Crossref
Mitchell E. Hughes & Jennifer Gill. (2018) Primer on Chronic Lymphocytic Leukemia: Part II. The Journal for Nurse Practitioners 14:4, pages 309-315.e2.
Crossref
Alma O'Reilly, James Murphy, Sarah Rawe & Mary Garvey. (2018) Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients. Clinical Lymphoma Myeloma and Leukemia 18:4, pages 249-256.
Crossref
Zar Ni Soe & David Allsup. (2017) The use of ofatumumab in the treatment of B-cell malignancies. Future Oncology 13:29, pages 2611-2628.
Crossref
Prithviraj Bose & Varsha Gandhi. (2017) Recent therapeutic advances in chronic lymphocytic leukemia. F1000Research 6, pages 1924.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.